title: [Predictive factors of lost to follow-up status during tuberculosis treatment].
abstract: BACKGROUND
  Patients with contagious tuberculosis who are lost to follow-up risk sowing the disease among their circle of acquaintances. Moreover, a history of inadequate anti-tuberculous treatment is an important risk factor for the development of drug-resistant organisms. The purpose of this study was to identify risk factors for loss to follow-up among patients undergoing treatment for tuberculosis.
  
  
  METHODS
  We performed a prospective cohort study among patients with contagious tuberculosis, beginning with anti-tuberculous treatment followed during six months, after initial education-information about their condition. We compared the characteristics of 152 patients lost to follow-up from tuberculosis treatment against those of 492 patients who were not lost to follow-up.
  
  
  RESULTS
  Independent factors associated with a reduction in the risk of being lost to follow-up were: the presence of night-sweats (OR=0.46 [0.24-0.88]; P=0.018), the presence of thoracic pain (OR=0.27 [0.14-0.54]; P<0.001), screening for HIV (OR=0.41 [0.17-0.98]; P=0.045), fact to inform a person of its disease (OR=0.06 [0.01-0.41]; P=0.004), the application of directly observed treatment in the community (OR=0.34 [0.17-0.66]; P<0.001).
  
  
  CONCLUSIONS
  Reducing loss to follow-up during treatment for tuberculosis requires the development of a "good attitude" through education-information about tuberculosis.
authors.affiliation: Service de pneumologie du CHU de Cocody, BP 582 Abidjan cedex 03, Côte d'Ivoire. kigninlmanh@yahoo.fr
authors.forename: K
authors.initials: K
authors.lastname: Horo
authors.forename: A B
authors.initials: AB
authors.lastname: Kouassi
authors.forename: C V
authors.initials: CV
authors.lastname: Brou-Gode
authors.forename: J-M B
authors.initials: JM
authors.lastname: Ahui
authors.forename: A
authors.initials: A
authors.lastname: Diaw
authors.forename: F
authors.initials: F
authors.lastname: Kone-Konate
authors.forename: K
authors.initials: K
authors.lastname: Toure
authors.forename: A Z
authors.initials: AZ
authors.lastname: Gnaze
authors.forename: S A
authors.initials: SA
authors.lastname: N'Gom
authors.forename: B N
authors.initials: BN
authors.lastname: Koffi
authors.forename: E
authors.initials: E
authors.lastname: Aka-Danguy
mesh_terms: D015492:AIDS Serodiagnosis / Q000706:statistics & numerical data; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D002637:Chest Pain / Q000453:epidemiology; D015897:Comorbidity; D007560:Cote d'Ivoire / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D015528:HIV Seroprevalence; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts / Q000523:psychology / Q000706:statistics & numerical data*; D010353:Patient Education as Topic; D011446:Prospective Studies; D012307:Risk Factors; D012959:Socioeconomic Factors; D014376:Tuberculosis / Q000517:prevention & control* / Q000635:transmission; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology / Q000517:prevention & control; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000523:psychology*; D055815:Young Adult; D016903:Drug Monitoring
chemical_list: D000995:Antitubercular Agents